Skip to content

The clinical study on the prevalence of metabolic syndrome (MS) in the primary breast cancer patients at initial diagnosis, during chemotherapy and after systematic therapy.

The clinical study on the prevalence of metabolic syndrome (MS) in the primary breast cancer patients at initial diagnosis, during chemotherapy and after systematic therapy.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOB-15007543
Enrollment
Unknown
Registered
2015-12-09
Start date
1990-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Case series:Nil

Sponsors

Department of Endocrine and Breast Surgery of the First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Group 1: Initial diagnosed with benign diseases of the breast by Department for Pathological Diagnosis in our hospital; The age between 18 and 75 years old; Informed consent was abtained from the participants; (2) Group 2: Initial diagnosed with breast cancer by Department for Pathological Diagnosis in our hospital or initial diagnosed by other hospitals but reviewed by us; The age between 18 and 75 years oldInformed consent was abtained from the participants; (3) Group 3: Diagnosed with breast cancer and during the period of chemotherapy(before the 5th or 6th cycle of chemotherapy); The age between 18 and 75 years old; Informed consent was abtained from the participants; (4) Group 4: More than three months after received systematic therapy; The age between 18 and 75 years old; Informed consent was abtained from the participants.

Exclusion criteria

Exclusion criteria: (1) Coexistence of other serious medical conditions, such as serious infections, organs failure, serious injury, etc.; (2) Those who cant stop taking medicines which have serious influence on blood sugar, blood pressure and blood lipid; (3) Repetitive ones in different stages of systematic therapy; (4) Those who need strict bed rest and inconvenience to be measured; (5) Informed consent was not abtained from the participants.

Design outcomes

Primary

MeasureTime frame
blood lipid;blood pressure;blood glucose;height;weight;waistline;hipline;

Countries

China

Contacts

Public ContactKong Lingquan
huihuikp@163.com+86 13101380893

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 25, 2026